Veeva DQS Hits Milestone With One Million Clinical Trial Subjects

The platform, known as Veeva DQS, focuses on reducing the administrative burden on clinical sites by integrating risk-based quality management directly into data workflows. According to Ibrahim Kamstrup-Akkaoui, a vice president at Novo, the system addresses the escalating challenge of managing massive data volumes generated by modern clinical research. The software enables teams to automate data classification and visualize critical metrics, aligning with regulatory standards like ICH E6(R3).

Beyond basic reconciliation, the system incorporates AI-driven classification that adapts to specific user roles and study needs. Pavel Burmenko, head of Veeva DQS strategy, noted that the technology shifts the focus of data managers from manual entry to strategic oversight. This evolution is further supported by the recently launched Veeva Study Builder Agent, which automates the configuration of electronic data capture systems directly from study protocols. These developments will be showcased at the upcoming Veeva R&D and Quality Summit in Boston.